HER2 Support Group Forums - View Single Post - VALANX Biotech secures ?3 million to advance LIV-1 ADC for metastatic triple-negative

News · 03-12-2026, 05:40 AM

VALANX Biotech (VALANX), a biotech company developing a technology for site-selectable, site-specific protein conjugation, today announced it has secured ?3 million to advance its lead antibody-drug conjugate (ADC) program.

More...

03-12-2026, 05:40 AM	#1
News Senior Member Join Date: Oct 2007 Posts: 20,111	VALANX Biotech secures ?3 million to advance LIV-1 ADC for metastatic triple-negative VALANX Biotech (VALANX), a biotech company developing a technology for site-selectable, site-specific protein conjugation, today announced it has secured ?3 million to advance its lead antibody-drug conjugate (ADC) program. More...